Let's Find Out Who Will Use It Before We Waste A Billion Dollars

The tragic loss of the space shuttle Challenger has not only disrupted the U.S. space program, it has also disrupted the process for planning the program. The current debate over the manned space station and the commercially developed space facility, an unmanned platform that would be launched and serviced by the shuttle in the early 1990s, is symptomatic of the present disarray. NASA’s problem is that it continues to employ a supply-side policy of investing in space. This is true for b

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

NASA’s problem is that it continues to employ a supply-side policy of investing in space. This is true for both the large manned space station and the industrial space facility (ISF). The development of hardware for the space station, for example, is far ahead of the development of experiments for the station. The science community that is dependent on NASA funding is properly concerned that, as with the shuttle, the station budget will make demands on NASA’s budget at the expense of planetary and space science.

The industrial space facility appears to be another example of such supply-side space policy. NASA wants to go ahead, even though no one has a clear sense of user requirements and priorities. The ISF is touted both as a near-term low-cost replacement for the space station and as a bridge to the development of the station. While one of these characterizations may be right, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • John Pike

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio